Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$0.85
-0.2%
$1.03
$0.71
▼
$3.31
$65.95M1.571.64 million shs1.99 million shs
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
$11.51
$11.51
$11.41
▼
$18.72
$63.37M-0.0414,430 shsN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
$2.68
-2.5%
$2.87
$1.83
▼
$5.12
$15.88M1.0928,069 shs7,670 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$1.78
-3.8%
$2.07
$1.78
▼
$2.73
$56.40M0.7676,941 shs62,583 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
+16.75%+5.87%-5.93%-4.33%-60.20%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
0.00%0.00%0.00%0.00%-0.78%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
+5.36%-1.08%+10.00%-18.88%-21.20%
XBiotech Inc. stock logo
XBIT
XBiotech
-5.61%-3.14%-12.74%-18.50%-29.92%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$0.85
-0.2%
$1.03
$0.71
▼
$3.31
$65.95M1.571.64 million shs1.99 million shs
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
$11.51
$11.51
$11.41
▼
$18.72
$63.37M-0.0414,430 shsN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
$2.68
-2.5%
$2.87
$1.83
▼
$5.12
$15.88M1.0928,069 shs7,670 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$1.78
-3.8%
$2.07
$1.78
▼
$2.73
$56.40M0.7676,941 shs62,583 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
+16.75%+5.87%-5.93%-4.33%-60.20%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
0.00%0.00%0.00%0.00%-0.78%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
+5.36%-1.08%+10.00%-18.88%-21.20%
XBiotech Inc. stock logo
XBIT
XBiotech
-5.61%-3.14%-12.74%-18.50%-29.92%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.29
Hold$7.50786.11% Upside
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
2.00
HoldN/AN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
2.00
Hold$23.00758.21% Upside
XBiotech Inc. stock logo
XBIT
XBiotech
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest NCEL, KVAC, CRDF, and XBIT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
XBiotech Inc. stock logo
XBIT
XBiotech
UpgradeSell (E+) ➝ Sell (D-)
11/9/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
UpgradeSell (E+) ➝ Sell (D-)
11/2/2026
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
UpgradeSell (D-) ➝ Sell (D)
10/30/2026
XBiotech Inc. stock logo
XBIT
XBiotech
DowngradeSell (D-) ➝ Sell (E+)
10/23/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
DowngradeSell (D-) ➝ Sell (E+)
10/16/2026
XBiotech Inc. stock logo
XBIT
XBiotech
UpgradeSell (E+) ➝ Sell (D-)
10/8/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
UpgradeSell (E+) ➝ Sell (D-)
9/28/2026
XBiotech Inc. stock logo
XBIT
XBiotech
DowngradeSell (D-) ➝ Sell (E+)
9/22/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
DowngradeSell (D-) ➝ Sell (E+)
9/18/2026
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
UpgradeSell (E+) ➝ Sell (D-)
9/15/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
UpgradeNeutral ➝ Buy
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$590K111.60N/AN/A$0.36 per share2.35
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/AN/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/AN/AN/AN/A$1.59 per shareN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/A$4.07 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.85M-$0.55N/AN/AN/A-6,736.49%-111.80%-81.51%N/A
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
-$8.30MN/AN/AN/AN/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
-$45.54M-$1.43N/AN/AN/AN/A-33.03%-31.57%N/A

Latest NCEL, KVAC, CRDF, and XBIT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.1380-$0.12+$0.0180-$0.12$0.08 million$0.17 million
11/12/2026Q3 2026
XBiotech Inc. stock logo
XBIT
XBiotech
$0.02-$0.15-$0.17-$0.15$7.00 millionN/A
9/18/2026Q2 2026
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/A-$0.48N/A-$0.48N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
4.21
4.21
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/A
0.40
N/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/A
39.51
33.15

Institutional Ownership

CompanyInstitutional Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
51.72%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/A
XBiotech Inc. stock logo
XBIT
XBiotech
55.70%

Insider Ownership

CompanyInsider Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
8.80%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
80.20%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
16.40%
XBiotech Inc. stock logo
XBIT
XBiotech
21.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
3177.79 million70.95 millionOptionable
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/A5.51 million1.09 millionNot Optionable
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
65.78 million4.83 millionNot Optionable
XBiotech Inc. stock logo
XBIT
XBiotech
8730.49 million24.06 millionOptionable

Recent News About These Companies

XBiotech: Q4 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$0.85 0.00 (-0.15%)
Closing price 04:00 PM Eastern
Extended Trading
$0.83 -0.02 (-2.41%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Keen Vision Acquisition stock logo

Keen Vision Acquisition NASDAQ:KVAC

$11.51 0.00 (0.00%)
As of 11/13/2026

Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.

NLS Pharmaceutics stock logo

NLS Pharmaceutics NASDAQ:NCEL

$2.68 -0.07 (-2.55%)
As of 02:53 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

XBiotech stock logo

XBiotech NASDAQ:XBIT

$1.78 -0.07 (-3.78%)
Closing price 04:00 PM Eastern
Extended Trading
$1.77 -0.01 (-0.56%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.